Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BCL9 | O00512 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16694512 | 0.99 | SIGMAR1 (0.50) | SIGMAR1HTR2AMAPTBCL9CTNNB1 | |
| Hydrochloric Acid SCHEMBL16694544 | 0.93 | HTR2A (0.46) | SIGMAR1HTR2AMAPTBCL9CTNNB1 | |
| SCHEMBL6816689 | 0.88 | SIGMAR1 (0.52) | SIGMAR1HTR2ABCL9CTNNB1CYP1A2 | |
| SCHEMBL314875 | 0.87 | SIGMAR1 (0.51) | SIGMAR1HTR2AMAPTKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL16694856 | 0.86 | ALDH1A1 (0.47) | SIGMAR1HTR2ABCL9CTNNB1CYP1A2 | |
| SCHEMBL5017678 | 0.86 | HTR2A (0.50) | SIGMAR1HTR2AMAPTBCL9CTNNB1 | |
| SCHEMBL29550444 | 0.86 | HTR2A (0.50) | SIGMAR1HTR2AMAPTBCL9CTNNB1 | |
| SCHEMBL6397367 | 0.85 | HTR2A (0.49) | SIGMAR1HTR2AMAPTBCL9CTNNB1 | |
| SCHEMBL313831 | 0.83 | ALDH1A1 (0.55) | SIGMAR1MAPTCYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL25184955 | 0.82 | HTR2A (0.47) | SIGMAR1HTR2ABCL9CTNNB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20110275670-A1 | New Compounds VII | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2321276-A1 | NEW COMPOUNDS VII | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| EP-2227461-A1 | NEW COMPOUNDS III | AstraZeneca AB (Publ) (SE) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009147219-A1 | NEW COMPOUNDS VII | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176798-A1 | New compounds III | GPR119, FABP4, GLP1R | SIGMAR1 1925/4885HTR2A 817/4885MAPT 4568/4885 |
| US-20110275670-A1 | New Compounds VII | GPR119, GLP1R, GIPR | SIGMAR1 1999/4885HTR2A 645/4885MAPT 4553/4885 |
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | SIGMAR1 2023/4885HTR2A 785/4885MAPT 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.